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Volume 51, Number 11S Abstracts 69Sincidence to be understated. In this ongoing study we com-
pared the incidence of arrhythmias using two different moni-
toring devices.
Methods: Patients with sinus rhythm were monitored
with a 72-hour Holter electrocardiography device (Holter-
ECG) (N  350), and combined with a subcutaneously
implanted cardiac loop recorder (Reveal XT®) (N  20),
the latter starting one month prior to surgery, until it was
explanted onemonth post-surgery. New-onset arrhythmias
were noted. Thirty-day postoperative events, defined as
MI, stroke, and cardiac death, were noted.
Results: New-onset perioperative arrhythmias were re-
corded in 45 (13%) and 8 (40%) patients with Holter-ECG
and Reveal respectively. In patients with perioperative ar-
rhythmias, cardiovascular events occurred more frequently
(OR 3.0, 95% CI 1.4-6.4). Using the Reveal device 4
additional patients were identified who experienced periop-
erative cardiovascular events. The incidence of cardiovascu-
lar events with Holter and Reveal monitoring was 11/45
(24%) and 4/8 (50%) respectively.
Conclusions: Vascular surgery patients may develop
paroxysmal arrhythmias outside the recording window of
the 72-hour Holter ECG and are generally asymptomatic.
Continuous implanted cardiac monitors can detect these
paroxysmal episodes of arrhythmias, which in turn could
have important therapeutic consequences.
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Objectives: This study is a multi-center, prospective,
randomized, controlled clinical trial that compared two
methods, the investigational Vascular Sealant and GEL-
FOAM®/Thrombin, for treating anastomotic bleeding.
The objective was to evaluate the safety and effectiveness of
the Vascular Sealant compared with GELFOAM®/
Thrombin when used to seal bleeding anastomotic suture
lines.
Methods: Patients were randomized into the Vascular
Sealant group or the Control GELFOAM®/Thrombin
group. The site (s) were assessed for bleeding immediately
and at intervals of 1, 3, 5, 7.5 and 10 minutes. Subjectswere assessed within 7 days of surgery and at 30 days
post-procedure.
Results: A total of 69 subjects were randomized. The
overall incidence of adverse events, including serious adverse
events, was comparable between the two study groups. Vas-
cular Sealant group sealing success was achieved for 90.7% of
treated subjects [95% CI: 79.7%, 96.9%] and in the Control
group, success was 86.7% [95% CI: 59.5%, 98.3%] (p 
0.072). The secondary endpoint of sealing success at the
anastomosis level was established to be noninferior to the
Control treatment (p  0.048). Immediate Sealing Success
was significantly greater for the Vascular Sealant group com-
pared with the Control group; 51.5% and 10.5%, respectively
(p 0.006).
Conclusions: Due to a small sample size the primary
endpoint did not reach significance. However secondary
endpoints did reach satistical significance and Vascular Seal-
ant appears to be as safe and effective as GELFOAM®/
Thrombin in stopping suture line bleeding. It has an ad-
vantage in achieving immediate hemostasis in over half the
cases. This product may be particularly suited for patients
on antiplatelet and/or anticoagulant agents as well as those
with known hemostatic deficiencies.
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Objectives: Endovascular aneurysm repair (EVAR) is
an established treatment for aortic aneurysm (AAA). Al-
though data is accumulating on radiation risk to patients,
little attention is paid to the radiation doses in individual
steps of EVAR. We aimed to divide an EVAR procedure
into dose related steps to facilitate dose optimization.
Methods: Dose area product (DAP), digital acquisi-
tion (DSA) and fluoroscopy times (FT) for 96 procedures
were analysed from our prospective EVAR database. Effec-
tive dose was calculated using this and computed tomog-
raphy (CT) dose data. Analysis of 7 procedures was used to
break the EVAR into a series of component steps according
to the radiation exposures. Phantom studies determined
the typical entrance surface dose for each procedure step for
the range of exposure parameters selected for the EVAR
procedures, including table height, position and field of
view (FOV).
ce,
ive
t,
e,
sis,
on
e,
sis
e,
1
1
JOURNAL OF VASCULAR SURGERY
June Supplement 201070S AbstractsResults: In the 96 patient study, mean effective dose
for EVAR was 12.6mSv (.23 - 80.9), and mean FT was
18.8mins (.2 - 64.6). Phantom studies determined patient
entrance dose for selected FOV (36, 28, 20 and 14cm) as
3.65, 5.32, 8.46 and 15.6mGy/min for Flouroscopy and
1.1, 1.94, 3.15 and 3.83mGy/frame for DSA. The 7
patient study showed mean number of digital frames was
191 (100 - 376) and maximum calculated skin dose was
1.3Gy, below deterministic injury threshold. Stochastic risk
for EVAR and associated CT was  1/800.
Conclusions:Our data confirms a significant variation in
radiation exposure during EVAR. We have combined clinical
and phantom data to calculate the radiation dose per individ-
ual step. This has the potential to be used as an educational
tool and to support optimization and dose reduction.
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Objectives: To evaluate our results when we employed
an ultrasound debridment system to treat infected grafts.
Methods: Patients with poor medical conditions and
those with unavailable autogenous grafts underwent an
accurate debridement of the grafts and surrounding tissue
with an ultrasonic debridement machinery. Complete graft
removal and Sartorius flap to cover the inguinal region were
selectively employed. We used a powerful ultrasonic gener-
ator (Genera, Italia Medica, Milan, Italy) which operates
activating a probe mounted on a piezoelectric transducer.
The probe vibrates at 26 KHz with a vibratory amplitude of
15-30 m and it is irrigated with normal saline. The probe
generates mechanical-vibratory and cavitational energy
which allow a complete debridement of the necrotic and
infected tissue. The caloric energy developed implements
the killing bacteria effect of the formers.
Results: 11 patients (median age 67 years) with a
prosthetic vascular graft infection (early in 9 cases and a late
in 2) received an extensive US debridement to allow the
lower invasive reconstruction to be performed (i.e. in situ vs
extra-anatomic). Estimated freedom from recurrent infec-
tion was 90, 1% at 6 months and 75, 8% at 1 and 2 years.
Conclusions: In our experience US debridement of in-
fected grafts obtained promising results. This allowed us to treat
patients more conservatively without compromising the chance
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